Study Collaboration Delivers Agility And Results During The COVID-19 Pandemic

A European multinational pharmaceutical company specializing in veterinary vaccines for more than 50 years needed extensive human vaccine experience to swiftly progress through clinical trials for its RBD dimer recombinant protein vaccine against SARS-CoV-2. To demonstrate the benefits of its BIMERVAX® vaccine in adult populations, HIPRA called on Veristat to assist with the planning and implementation of the pertinent scientific, operational, and biometrics aspects of its clinical trials, which included immunocompromised adults as part of the RBDCOV Project.

Discover how HIPRA gained support for several international studies to test efficacy, tolerability, and safety, and demonstrate the benefits of BIMERVAX®, resulting in a marketing authorization from the EMA on March 2023.